Background: Rifampicin is the key drug responsible for sterilizing activities in the first-line TB treatment regimen. Damage to the gut during acute and chronic HIV infection may inhibit drug absorptive capacity. We sought to test the hypothesis that markers of intestinal damage, bacterial translocation and systemic immune activation would relate to rifampicin bioavailability among HIV/TB patients.
Introduction
TB remains a leading cause of death among HIV-infected individuals worldwide. Among TB patients, HIV co-infection increases the risk of adverse treatment outcomes, including delayed sputum sterilization, relapse after completing therapy, acquisition of drugresistant disease and death. [1] [2] [3] [4] Rifampicin is the key drug responsible for sterilizing activities in the first-line TB regimen and it is likely that current dosing regimens 5 lead to exposures at the lower end of the dose-response curve. [6] [7] [8] Meta-analyses of TB treatment trials suggest that current weight-based dosing guidelines lead to rifampicin under-dosing for HIV-infected patients. 1 Previous efforts to link low rifampicin serum concentrations with CD4! T cell counts or HIV viral load have been unsuccessful and consequently HIV/TB patients at greatest risk for low rifampicin exposure cannot be identified at the time of therapy initiation. 9, 10 Intestinal lymphoid tissue is the site of dramatic early loss of CD4! T cells after HIV infection, which is accompanied by duodenal villous atrophy, crypt hyperplasia and sub-epithelial collagen deposition. [11] [12] [13] [14] Evidence for intestinal dysregulation identified in the peripheral blood of HIV-infected patients includes a protein synthesized by enterocytes that spills into blood during states of intestinal epithelial injury [intestinal fatty acid binding protein (I-FABP)] and a cell surface marker [soluble CD14 (sCD14)] that is shed upon activation of monocytes by microbial translocation products like LPS. 15, 16 These early changes develop concurrently with systemic immune activation, which typically decreases yet persists after the initiation of ART. 17, 18 A single measure of HIVassociated immune activation, the percent expression of CD38 and HLA-DR on CD8! T cells (%CD38 ! DR ! CD8!), carries greater prognostic significance than CD4! T cell counts or HIV viral load. 19, 20 In the case of the companion first-line anti-TB agent, isoniazid, we found that increasing levels of %CD38 ! DR ! CD8! were associated with decreasing isoniazid clearance. 21 Damage to the gut during acute and chronic HIV infection may exert a profound effect on drug absorptive capacity, decreasing the oral bioavailability of certain drugs. Rifampicin malabsorption has been linked with impaired intestinal absorptive capacity, as measured by the D-xylose assay. 22, 23 Intestinal barrier function was reduced among Brazilian TB patients, compared with healthy controls, as measured by paracellular transport of lactulose. 24 In addition, TB patients with MDR disease, defined as resistance to both rifampicin and isoniazid, demonstrated decreased intestinal absorptive capacity compared with TB patients with drug-susceptible disease. 25 Poor oral bioavailability would reduce both rifampicin peak concentration and area under the concentration-time curve from 0 to 24 h (AUC 0-24 ), linked directly to failure of therapy and emergence of acquired drug resistance. 26, 27 Furthermore, nutritional supplementation was recently shown to improve the oral bioavailability of rifampicin among HIV/TB patients in Tanzania. 28 We sought to test the hypothesis that increased markers of intestinal damage, bacterial translocation and systemic immune activation would be associated with low rifampicin bioavailability among HIV/TB patients.
Patients and methods

Ethics
Written informed consent was obtained from all patients and the study was approved by institutional review boards of the Ministry of Health of Botswana and the University of Pennsylvania (approval reference number 819344).
Study design
We conducted a prospective cohort study of rifampicin pharmacokinetics among HIV/TB patients recruited from 22 public clinics and Princess Marina Hospital in Gaborone, Botswana.
Study population
HIV-infected adults (21 years of age and older) were eligible for enrolment if they were citizens of Botswana, naive to ART and newly diagnosed with pulmonary TB. Patients must have been initiated on a standard first-line TB treatment regimen with isoniazid, rifampicin, ethambutol and pyrazinamide, following WHO guidelines for weight-based dosing bands. 5 Treatment was administered as directly observed therapy using fixed-dose combinations and the intensive phase of treatment continued for 2 months. The diagnosis of pulmonary TB must have been established by either a positive sputum smear, a positive GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) or the presence of WHO criteria for smearnegative pulmonary TB. 5 Exclusion criteria included pregnancy, renal insufficiency (defined as a creatinine clearance less than 50 mL/min) and hepatic dysfunction (defined as either ALT or AST greater than three times the upper limit of normal or 165 U/L and 102 U/L, respectively). The study population has been previously described in a report on isoniazid population pharmacokinetics. 21 
Data collection
The study procedures consisted of two pharmacokinetic study visits, with each visit conducted at a public clinic associated with Princess Marina Hospital. The first pharmacokinetic study visit was designed to occur between 5 and 28 days after the initiation of anti-TB therapy, corresponding to steady-state conditions during the intensive treatment phase. All participants were eligible to return for a second pharmacokinetic visit during the intermittent phase of anti-TB therapy, provided that ART had also been initiated. Intermittent phase treatment included rifampicin and isoniazid for an additional 4 months. The second pharmacokinetic visit was designed to occur after approximately 4 weeks of ART, when systemic immune activation levels can change dramatically in either direction. 29 The procedures for each pharmacokinetic study visit were identical. After an overnight fast, oral doses of the anti-TB drugs were obtained from the Gaborone City Clinic and directly administered to the participant on the morning of the pharmacokinetic study visit. A baseline blood sample was drawn and anti-TB therapy was administered under directly observed therapy. Pharmacokinetic blood samples (10 mL) were drawn at 0.3, 0.9, 2.2, 4.5 and 8 h post-dosing. These sampling times were selected based on optimal sampling theory for isoniazid, rifampicin and pyrazinamide pharmacokinetics. Covariate information gathered included age, weight, BMI, gender, serum creatinine, HIV viral load and CD4! T cell count. We quantified intestinal damage and microbial translocation by measuring peripheral blood levels of I-FABP and sCD14, respectively. HIV-associated systemic immune activation was measured by %CD38 ! DR ! CD8! and plasma IL-6 concentrations.
Analytical methods
Markers of gut damage and immune activation
Blood samples were transported to the Botswana Harvard Partnership Laboratory upon collection for plasma and PBMC isolation using FicollPaque Plus (GE Healthcare) density gradient centrifugation. Plasma, previously frozen at #70 C, was diluted 2-fold and 500-fold to determine concentrations of I-FABP (Hycult Biotech, Plymouth Meeting, PA, USA) and CD14 (R&D Systems, Minneapolis, MN, USA), respectively. Undiluted plasma was used to determine concentrations of IL-6 (R&D Systems). Assays were conducted as per the manufacturers' protocols. We determined %CD38 ! DR ! CD8! T cells using previously described methods. 21 
Serum rifampicin concentrations
Cryopreserved serum samples for each time point were shipped to the Gumbo Laboratory at the Baylor Research Institute (Dallas, TX, USA). Rifampicin concentrations were measured with LC-tandem MS methods as previously described.
21
SLCO1B1 genotype
Blood samples were shipped to the Gumbo lab at the Baylor Research Institute for whole exome sequencing and used to determine variation in the SLCO1B1 gene that encodes OATP1B1, a solute carrier organic anion transporter that is involved in the active influx of endogenous and xenobiotic compounds. 30 Two variant alleles at rs4149032 and rs11045819 in SLCO1B1 have been linked to decreased oral bioavailability of rifampicin.
31,32
Statistical analysis Non-linear mixed-effects modelling of pharmacokinetic data Non-linear mixed-effects modelling was performed to estimate the pharmacokinetic parameters for bioavailability, absorption, volume of distribution and clearance. 33 Model development used first-order conditional estimation in Phoenix NLME 1.3 (Certara) to provide estimates of the typical values for population pharmacokinetic parameters, between-subject variability and residual variability. For nested models, a reduction in the objective function value greater than 3.84 for a difference of one degree of freedom was considered statistically significant (P , 0.05), assuming a v 2 distribution. Goodness-of-fit was examined visually with plots of Gut dysfunction and rifampicin bioavailability in HIV/TB JAC observed versus population predicted concentration, observed versus individual predicted concentrations, individual weighted residuals versus individual predicted concentrations and conditional weighted residuals versus time.
Rifampicin serum concentration-versus-time data were fitted to oneand two-compartment models with first-order elimination. Rifampicin absorption was assessed with a first-order absorption model, with and without an absorption lag, and a transit compartment absorption model. 34 Inter-occasional variability on each parameter was examined with a mean of zero and variance j2. Between-subject variability was examined with an exponential variability model with mean of zero and variance x2. Additive, proportional and combined residual error models were tested to describe residual unexplained variability. Covariance between each parameter's between-subject variability was evaluated in a variance-covariance matrix.
Plots of the random effects on pharmacokinetic parameters versus the individual covariates provided insight into potential covariate effects. The final model was selected based on biological plausibility, goodness-of-fit as evidenced by visual examination of diagnostic plots and statistical criteria. Visual predictive checks were used to evaluate the performance of candidate and final models for rifampicin pharmacokinetics, by simulation of 1000 datasets. The distribution (median and 5th and 95th percentiles) of the simulated concentrations versus time was compared with the distribution of the observed values in the original dataset. Differences and overlap of the simulated and original distributions indicated the accuracy of the identified model.
Results
Out of 61 patients screened, 40 patients were enrolled in the study and completed the first pharmacokinetic study visit. The median age was 32 years (IQR 27-43 years) and the median CD4! T cell count was 238 cells/lL (IQR 105-339 cells/lL). Based on weightbased rifampicin dosing guidelines, 5 the rifampicin dose sizes at the first study visit included 300 mg (1 individual), 450 mg (19 individuals), 600 mg (17 individuals) and 750 mg (3 individuals). These dose sizes corresponded to a range of 7.9-12.5 mg/kg (median 9.7 mg/kg) rifampicin dosing in the study population.
Following the first pharmacokinetic study visit, we obtained separate informed consent for individuals to return for a second pharmacokinetic study visit after initiating ART. Fifteen of 40 patients elected not to return for the second visit and one patient was ineligible due to delayed initiation of ART. Thus, 24 patients returned for the second visit, performed approximately 4 weeks after the initiation of ART. All patients received the combination of tenofovir, emtricitabine and efavirenz as their ART regimen. At the time of the second pharmacokinetic study visit, the median duration of anti-TB therapy was 74 days (range 37-118 days). All patients had been receiving ART for a median of 33 days (range 5-44 days). Clinical and demographic characteristics of study participants have been previously reported. 21 We examined two SLCO1B1 variant alleles previously found to be associated with decreased rifampicin exposure. 31, 32 The rs11045819 allele (C463A) was found as a heterozygote variant in 4 of 40 individuals (10%) and as a homozygous variant in one individual (3%). In non-compartmental analysis, a significant difference in AUC 0-8 was found for the rs11045819 allele, with a lower AUC 0-8 in the heterozygous individuals (median 19.2 mgÁh/L) compared with homozygous WT (median 32.6 mgÁh/L, P " 0.006). Interestingly, a single patient was homozygous for the rs11045819 variant allele, with much greater rifampicin AUC 0-8 at the first study visit (66.2 mgÁh/L). Mean rifampicin concentration-versus-time plots are shown in Figure 1 , grouped by rs11045819 allele genotype. The rs4149032 allele (T521C) was found as a heterozygous variant in 14 individuals (35%) and as a homozygous variant in 23 individuals (58%). Thus, only 3 of 40 individuals (8%) were homozygous for the reference rs4149032 allele. There were no differences in rifampicin AUC 0-8 between rs4149032 allele groups.
The pairwise correlation of markers of intestinal damage (I-FABP) and microbial translocation (sCD14) with %CD38 ! DR ! CD8! and CD4! T cell counts, prior to the initiation of ART, are shown in Figure S1 (available as Supplementary data at JAC Online). The correlation between sCD14 and %CD38 ! DR ! CD8! reached statistical significance (r " 0.39, P " 0.016), but all other correlations were non-significant. The changes in I-FABP and sCD14, before and after the initiation of ART, are shown in Figure 2 . Among individuals with paired data, there was a significant increase in I-FABP levels (P , 0.001 by the Wilcoxon sign rank test), while there was no difference in sCD14 levels (P " 0.17).
The rifampicin serum concentration-versus-time data were best explained by a one-compartment model with first-order elimination, and a combined additive and proportional residual error model. We evaluated absorption as a first-order process, with and without a time lag, and a transit compartment process. The data were best described with the transit compartment model, with parameters for the number of absorption compartments and the mean transit time within an absorption compartment. The structural model supported between-subject variability on the clearance, bioavailability, number of transit compartments and mean transit time, along with inter-occasional variability on bioavailability (Table 1) .
Next, we evaluated markers of intestinal damage (I-FABP), microbial translocation (sCD14) and systemic immune activation (%CD38 ! DR ! CD8! and plasma IL-6 concentrations) as covariates on rifampicin bioavailability. The eta-covariate plots for each of these markers ( Figure S2 ) did not support a relationship between variability in these HIV disease markers and rifampicin bioavailability. The pharmacokinetic models that included each of these markers as covariates on rifampicin bioavailability, including the inter-occasional variability before and after ART initiation, did not lead to significant reductions in the objective function value (Table 2) . Thus, variability in markers of gut damage, microbial translocation and immune activation did not contribute to variability in the oral bioavailability of rifampicin.
Diagnostic plots for the final pharmacokinetic model are shown in Figure S3 , including plots of observed versus population predicted concentrations (Figure S3a) , observed versus individual predicted concentrations (Figure S3b ), individual weighted residuals versus individual predicted concentrations ( Figure S3c ) and conditional weighted residuals versus individual predicted concentrations ( Figure S3d ). The visual predictive checks for the final model are shown in Figure S4 .
The individual predicted rifampicin pharmacokinetic parameters are shown in Figure S5 and changes in rifampicin C max and AUC 0-24 are shown in Figure 3 , before and after the initiation of ART. The median rifampicin C max prior to initiation of ART was 7.4 mg/L (range 2.56-11.61 mg/L), compared with 7.2 mg/L (range 3.63-13.19 mg/L) after the initiation of ART (P " 0.98) (Figure 3a) . Sixteen of 40 individuals (40%) had a rifampicin C max below the target identified by Pasipanodya et al. 26 to predict 2 month sputum culture conversion prior to the initiation of ART Vinnard et al. 
Discussion
In this prospective study of 40 HIV/TB patients undergoing pharmacokinetic sampling before and after the initiation of ART, we did not observe a relationship between rifampicin bioavailability and HIV-associated markers of intestinal damage, microbial translocation or systemic immune activation. The rifampicin population pharmacokinetic parameters that we report are similar to those from previous studies from sub-Saharan Africa. [35] [36] [37] Thus, although low rifampicin exposure frequently occurred in the study population, it could not be explained by variability in these biomarkers, which predict HIV disease progression.
Pharmacokinetic variability is an important driver of poor outcomes of TB therapy, including the emergence of drug resistance during treatment. 26, 38 Our findings add to the work of others demonstrating the difficulty in predicting which patients will have sub-optimal rifampicin exposures during TB therapy and provide additional evidence that current rifampicin dosing guidelines contribute to low exposures in many TB patients. 7, 8 The recently Gut dysfunction and rifampicin bioavailability in HIV/TB JAC revised American Thoracic Society/CDC/IDSA guidelines for the treatment of drug-susceptible TB note that therapeutic drug monitoring may be particularly helpful in the management of HIV/TB patients. 39 Our findings contrast with a recent study of HIV/TB patients in Burkina Faso evaluating rifampicin pharmacokinetics at baseline, and after 2 weeks and 10 weeks of ART, where a significant increase in rifampicin AUC 0-24 was observed. 40 The mechanism for these divergent findings is uncertain, but may include differences in pharmacogenetics (including SLCO1B1) and drug formulations. In that study, the median rifampicin C max value prior to ART initiation was 2.2 mg/L, compared with 7.4 mg/L in our study. It is also noteworthy that the patients in Burkina Faso received nevirapine-based ART, as compared with efavirenz-based ART in our study.
One surprising result was the increase in levels of intestinal damage (as measured by I-FABP) after the initiation of ART. Although levels of I-FABP prior to ART initiation have prognostic significance for HIV disease progression, 16 less is known about dynamic changes during ART treatment. Among patients treated with ART for acute HIV infection, markers of enterocyte damage (including I-FABP) increased during the first 2 weeks of treatment and remained above baseline levels for the entire 96 week period of follow-up. 41 Interestingly, lower I-FABP levels among HIV/TB patients have been associated with the development of immune reconstitution inflammatory syndrome. Vinnard et al.
The mechanism for increases in I-FABP during HIV/TB therapy, and its prognostic significance, remain to be identified in future studies.
This study had several limitations. Rifampicin undergoes autoinduction of clearance during therapy 43 and due to the timing of pharmacokinetic study visits we were unable to independently estimate baseline and steady-state clearance parameters. Given the range of the initial pharmacokinetic sampling visit, this autoinduction effect may have contributed to between-subject and inter-occasional variability in rifampicin clearance. The highly skewed distribution of SLCO1B1 genotypes in the study population prevented formal evaluation of genotype effects in the population pharmacokinetic model. Furthermore, we did not measure serum concentrations of the ART medications, such as efavirenz. Thus, we could not examine the relationship of ART pharmacokinetic variability (for example, due to different rates of efavirenz auto-induction) with changes in intestinal damage markers or with the unexplained variability in rifampicin pharmacokinetics. Finally, this study was not powered to assess the effect of rifampicin pharmacokinetic variability on clinical endpoints.
In summary, markers of intestinal damage, microbial translocation and systemic immune activation did not explain variability in rifampicin pharmacokinetic parameters, including bioavailability. The a priori identification of HIV/TB patients at risk for low rifampicin concentrations remains a challenge, supporting a role for therapeutic drug monitoring during HIV/TB therapy.
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